二甲双胍辅助治疗糖尿病合并耐多药结核病的研究进展OA北大核心CSTPCD

Tuberculosis caused by Mycobacterium tuberculosis is a major global infectious disease.Diabetes mellitus can increase the risk of tuberculosis and worsen the treatment outcomes of tuberculosis,and also make mycobacterium tuberculosis more resistant to drugs.The treatment situation for patients with multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis remains severe globally,and there is an urgent need to find new therapies that are effective,safe,and shorten the duration of treatment.Studies have shown that therapeutic modulation of the immune response of tuberculosis patients can promote the elimination of mycobacterium tuberculosis and limit excessive pathological reactions,known as host-directed therapy.Metformin(MET)is a drug approved for the treatment of type 2 diabetes mellitus.Recently,a large number of studies have shown the benefits of MET for tuberculosis patients,which may complement novel therapies for drug-resistant mycobacterium tuberculosis.This article discusses the research progress of metformin as a potential host-directed therapy for the treatment of multidrug-resistant tuberculosis against the backdrop of the co-epidemic of diabetes and tuberculosis.